Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases

BACKGROUND: Dacomitinib is a second‐generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) which is superior to first‐generation EGFR TKI in ARCHER 1050. However, the activity of dacomitinib in the central nervous system (CNS) is not known as ARCHER 1050 did not include p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jinyao, Wang, Yan, Liu, Ziling, Wang, Lin, Yao, Yu, Liu, Yutao, Hao, Xue Zhi, Wang, Jianyang, Xing, Puyuan, Li, Junling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671892/
https://www.ncbi.nlm.nih.gov/pubmed/34751504
http://dx.doi.org/10.1111/1759-7714.14222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671892/
https://www.ncbi.nlm.nih.gov/pubmed/34751504
http://dx.doi.org/10.1111/1759-7714.14222

Ejemplares similares